Skip to Main Content

Paper Details

EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
J Neurooncol
24
2019
EGFR, EGFR gene, GBM, Patients, VEGF antibody, bevacizumab, classical tumors, glioblastoma, malignant brain tumor, patients, recurrent, tumor
Author NameAffiliation
Cameron BrennanMemorial Sloan Kettering Cancer Center
Jason T HuseM.D. Anderson Cancer Center
Yoshua EsquenaziMemorial Sloan Kettering Cancer Center
Katherine S PanageasMemorial Sloan Kettering Cancer Center
  • 1 - 4

Datasets

Release 1.2